Optiscan rights issue closes, securing $17.75m for strategic transformation

Optiscan Imaging Ltd (ASX:OIL) successfully closed its fully underwritten pro-rata renounceable entitlement offer on September 16, 2025, raising approximately AUD17.75 million. The offer, which allowed shareholders to subscribe for one new share for every four held at AUD0.085 per share, aims to fund the company's evolution into a medical device manufacturer and digital healthcare solution provider.

The offer received strong support, with entitlements applied for totaling AUD9,809,000.85, corresponding to 115,400,004 shares. An additional AUD155,768.61 was raised from eligible shareholders applying through the shortfall, accounting for 1,832,572 shares. The total funds raised, including the portion allocated to the underwriter, amounted to AUD17,617,830.49 for 207,268,594 shares.

Peters Investments Pty Ltd acted as the underwriter for the offer, covering the remaining shortfall of AUD7,786,276.51 (91,603,253 shares). Optiscan anticipates issuing and allotting all new shares under the offer on Tuesday, September 23, 2025, and extended its appreciation to participating shareholders for their ongoing support.